APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antisense Oligonucleotide Therapies

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antisense Oligonucleotide Therapies Market Analysis and Forecast 2026-2032

31 December 2025190 pages

Choose your research edition.

Industry ResearchAntisense Oligonucleotide Therapies Industry Research Report 2026103 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense Oligonucleotide Therapies Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Antisense Oligonucleotide Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense Oligonucleotide Therapies Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense Oligonucleotide Therapies Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Antisense Oligonucleotide Therapies market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Antisense Oligonucleotide Therapies include Sarepta Therapeutics, Nippon Shinyaku and Ionis Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Antisense Oligonucleotide Therapies, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antisense Oligonucleotide Therapies, also provides the revenue of main regions and countries. Of the upcoming market potential for Antisense Oligonucleotide Therapies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antisense Oligonucleotide Therapies revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antisense Oligonucleotide Therapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Antisense Oligonucleotide Therapies revenue, projected growth trends, production technology, application and end-user industry.

Antisense Oligonucleotide Therapies Segment by Company

Sarepta Therapeutics

Nippon Shinyaku

Ionis Pharmaceuticals

Antisense Oligonucleotide Therapies Segment by Type

Without GalNAc-conjugated

With GalNAc-conjugated

Antisense Oligonucleotide Therapies Segment by Application

Cancer

Cardiovascular Diseases

Genetic Disease

Other

Antisense Oligonucleotide Therapies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense Oligonucleotide Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense Oligonucleotide Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense Oligonucleotide Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Antisense Oligonucleotide Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Antisense Oligonucleotide Therapies company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antisense Oligonucleotide Therapies revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Without GalNAc-conjugated Major Player Table 3. With GalNAc-conjugated Major Player Table 4. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cancer Major Player Table 6. Cardiovascular Diseases Major Player Table 7. Genetic Disease Major Player Table 8. Other Major Player Table 9. Antisense Oligonucleotide Therapies Industry Trends Table 10. Antisense Oligonucleotide Therapies Industry Drivers Table 11. Antisense Oligonucleotide Therapies Industry Opportunities and Challenges Table 12. Antisense Oligonucleotide Therapies Industry Restraints Table 13. Global Antisense Oligonucleotide Therapies Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Antisense Oligonucleotide Therapies Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Antisense Oligonucleotide Therapies Market Share by Region (2021-2026) Table 16. Global Antisense Oligonucleotide Therapies Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Antisense Oligonucleotide Therapies Market Share by Region (2027-2032) Table 18. Global Antisense Oligonucleotide Therapies Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Antisense Oligonucleotide Therapies Revenue Market Share by Players (2021-2026) Table 20. Global Antisense Oligonucleotide Therapies Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Antisense Oligonucleotide Therapies Key Players Headquarters & Area Served Table 22. Global Antisense Oligonucleotide Therapies Players, Product Type & Application Table 23. Global Antisense Oligonucleotide Therapies Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Antisense Oligonucleotide Therapies by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Antisense Oligonucleotide Therapies Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Antisense Oligonucleotide Therapies Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Antisense Oligonucleotide Therapies Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2021-2026) Table 30. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2027-2032) Table 31. Global Antisense Oligonucleotide Therapies Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Antisense Oligonucleotide Therapies Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Antisense Oligonucleotide Therapies Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Antisense Oligonucleotide Therapies Revenue Market Share by Application (2021-2026) Table 35. Global Antisense Oligonucleotide Therapies Revenue Market Share by Application (2027-2032) Table 36. Sarepta Therapeutics Company Information Table 37. Sarepta Therapeutics Business Overview Table 38. Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sarepta Therapeutics Antisense Oligonucleotide Therapies Product Portfolio Table 40. Sarepta Therapeutics Recent Development Table 41. Nippon Shinyaku Company Information Table 42. Nippon Shinyaku Business Overview Table 43. Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Nippon Shinyaku Antisense Oligonucleotide Therapies Product Portfolio Table 45. Nippon Shinyaku Recent Development Table 46. Ionis Pharmaceuticals Company Information Table 47. Ionis Pharmaceuticals Business Overview Table 48. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product Portfolio Table 50. Ionis Pharmaceuticals Recent Development Table 51. North America Antisense Oligonucleotide Therapies Revenue by Type (2021-2026) & (US$ Million) Table 52. North America Antisense Oligonucleotide Therapies Revenue by Type (2027-2032) & (US$ Million) Table 53. North America Antisense Oligonucleotide Therapies Revenue by Application (2021-2026) & (US$ Million) Table 54. North America Antisense Oligonucleotide Therapies Revenue by Application (2027-2032) & (US$ Million) Table 55. North America Antisense Oligonucleotide Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 56. North America Antisense Oligonucleotide Therapies Revenue by Country (2021-2026) & (US$ Million) Table 57. North America Antisense Oligonucleotide Therapies Revenue by Country (US$ Million) & (2027-2032) Table 58. Europe Antisense Oligonucleotide Therapies Revenue by Type (2021-2026) & (US$ Million) Table 59. Europe Antisense Oligonucleotide Therapies Revenue by Type (2027-2032) & (US$ Million) Table 60. Europe Antisense Oligonucleotide Therapies Revenue by Application (2021-2026) & (US$ Million) Table 61. Europe Antisense Oligonucleotide Therapies Revenue by Application (2027-2032) & (US$ Million) Table 62. Europe Antisense Oligonucleotide Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 63. Europe Antisense Oligonucleotide Therapies Revenue by Country (2021-2026) & (US$ Million) Table 64. Europe Antisense Oligonucleotide Therapies Revenue by Country (US$ Million) & (2027-2032) Table 65. China Antisense Oligonucleotide Therapies Revenue by Type (2021-2026) & (US$ Million) Table 66. China Antisense Oligonucleotide Therapies Revenue by Type (2027-2032) & (US$ Million) Table 67. China Antisense Oligonucleotide Therapies Revenue by Application (2021-2026) & (US$ Million) Table 68. China Antisense Oligonucleotide Therapies Revenue by Application (2027-2032) & (US$ Million) Table 69. Asia Antisense Oligonucleotide Therapies Revenue by Type (2021-2026) & (US$ Million) Table 70. Asia Antisense Oligonucleotide Therapies Revenue by Type (2027-2032) & (US$ Million) Table 71. Asia Antisense Oligonucleotide Therapies Revenue by Application (2021-2026) & (US$ Million) Table 72. Asia Antisense Oligonucleotide Therapies Revenue by Application (2027-2032) & (US$ Million) Table 73. Asia Antisense Oligonucleotide Therapies Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 74. Asia Antisense Oligonucleotide Therapies Revenue by Region (US$ Million) & (2021-2026) Table 75. Asia Antisense Oligonucleotide Therapies Revenue by Region (US$ Million) & (2027-2032) Table 76. SAMEA Antisense Oligonucleotide Therapies Revenue by Type (2021-2026) & (US$ Million) Table 77. SAMEA Antisense Oligonucleotide Therapies Revenue by Type (2027-2032) & (US$ Million) Table 78. SAMEA Antisense Oligonucleotide Therapies Revenue by Application (2021-2026) & (US$ Million) Table 79. SAMEA Antisense Oligonucleotide Therapies Revenue by Application (2027-2032) & (US$ Million) Table 80. SAMEA Antisense Oligonucleotide Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. SAMEA Antisense Oligonucleotide Therapies Revenue by Country (2021-2026) & (US$ Million) Table 82. SAMEA Antisense Oligonucleotide Therapies Revenue by Country (US$ Million) & (2027-2032) Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Antisense Oligonucleotide Therapies Image Figure 2. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antisense Oligonucleotide Therapies Market Size Share 2021 VS 2025 VS 2032 Figure 4. Without GalNAc-conjugated Image Figure 5. With GalNAc-conjugated Image Figure 6. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Antisense Oligonucleotide Therapies Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cancer Image Figure 9. Cardiovascular Diseases Image Figure 10. Genetic Disease Image Figure 11. Other Image Figure 12. Global Antisense Oligonucleotide Therapies Market Size (US$ Million) & (2021-2032) Figure 13. Global Antisense Oligonucleotide Therapies Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Antisense Oligonucleotide Therapies Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Antisense Oligonucleotide Therapies Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Antisense Oligonucleotide Therapies Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Antisense Oligonucleotide Therapies Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2021-2032) Figure 20. Global Antisense Oligonucleotide Therapies Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Antisense Oligonucleotide Therapies Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Antisense Oligonucleotide Therapies Revenue Market Share by Application (2021-2032) Figure 23. North America Antisense Oligonucleotide Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Antisense Oligonucleotide Therapies Revenue Share by Type (2021-2032) Figure 25. North America Antisense Oligonucleotide Therapies Revenue Share by Application (2021-2032) Figure 26. North America Antisense Oligonucleotide Therapies Revenue Share by Country (2021-2032) Figure 27. United States Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Antisense Oligonucleotide Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Antisense Oligonucleotide Therapies Revenue Share by Type (2021-2032) Figure 32. Europe Antisense Oligonucleotide Therapies Revenue Share by Application (2021-2032) Figure 33. Europe Antisense Oligonucleotide Therapies Revenue Share by Country (2021-2032) Figure 34. Germany Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Antisense Oligonucleotide Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Antisense Oligonucleotide Therapies Revenue Share by Type (2021-2032) Figure 44. China Antisense Oligonucleotide Therapies Revenue Share by Application (2021-2032) Figure 45. Asia Antisense Oligonucleotide Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Antisense Oligonucleotide Therapies Revenue Share by Type (2021-2032) Figure 47. Asia Antisense Oligonucleotide Therapies Revenue Share by Application (2021-2032) Figure 48. Asia Antisense Oligonucleotide Therapies Revenue Share by Region (2021-2032) Figure 49. Japan Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Antisense Oligonucleotide Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Antisense Oligonucleotide Therapies Revenue Share by Type (2021-2032) Figure 57. SAMEA Antisense Oligonucleotide Therapies Revenue Share by Application (2021-2032) Figure 58. SAMEA Antisense Oligonucleotide Therapies Revenue Share by Country (2021-2032) Figure 59. Brazil Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Antisense Oligonucleotide Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Without GalNAc-conjugated
  • With GalNAc-conjugated
Applications
  • Cancer
  • Cardiovascular Diseases
  • Genetic Disease
  • Other
Companies covered
  • Sarepta Therapeutics
  • Nippon Shinyaku
  • Ionis Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antisense Oligonucleotide Therapies Market by Type
  3. 1.2.1 Global Antisense Oligonucleotide Therapies Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Without GalNAc-conjugated
  5. 1.2.3 With GalNAc-conjugated
  6. 1.3 Antisense Oligonucleotide Therapies Market by Application
  7. 1.3.1 Global Antisense Oligonucleotide Therapies Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Cardiovascular Diseases
  10. 1.3.4 Genetic Disease
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Antisense Oligonucleotide Therapies Market Dynamics
  1. 2.1 Antisense Oligonucleotide Therapies Industry Trends
  2. 2.2 Antisense Oligonucleotide Therapies Industry Drivers
  3. 2.3 Antisense Oligonucleotide Therapies Industry Opportunities and Challenges
  4. 2.4 Antisense Oligonucleotide Therapies Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Antisense Oligonucleotide Therapies Market Perspective (2021-2032)
  2. 3.2 Global Antisense Oligonucleotide Therapies Growth Trends by Region
  3. 3.2.1 Global Antisense Oligonucleotide Therapies Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antisense Oligonucleotide Therapies Market Size by Region (2021-2026)
  5. 3.2.3 Global Antisense Oligonucleotide Therapies Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Antisense Oligonucleotide Therapies Revenue by Players
  2. 4.1.1 Global Antisense Oligonucleotide Therapies Revenue by Players (2021-2026)
  3. 4.1.2 Global Antisense Oligonucleotide Therapies Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Antisense Oligonucleotide Therapies Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antisense Oligonucleotide Therapies Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Antisense Oligonucleotide Therapies Key Players Headquarters & Area Served
  7. 4.4 Global Antisense Oligonucleotide Therapies Players, Product Type & Application
  8. 4.5 Global Antisense Oligonucleotide Therapies Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Antisense Oligonucleotide Therapies Market CR5 and HHI
  11. 4.6.3 2025 Antisense Oligonucleotide Therapies Tier 1, Tier 2, and Tier 3
5 Antisense Oligonucleotide Therapies Market Size by Type
  1. 5.1 Global Antisense Oligonucleotide Therapies Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Antisense Oligonucleotide Therapies Revenue by Type (2021-2032)
  3. 5.3 Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2021-2032)
6 Antisense Oligonucleotide Therapies Market Size by Application
  1. 6.1 Global Antisense Oligonucleotide Therapies Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Antisense Oligonucleotide Therapies Revenue by Application (2021-2032)
  3. 6.3 Global Antisense Oligonucleotide Therapies Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sarepta Therapeutics
  2. 7.1.1 Sarepta Therapeutics Company Information
  3. 7.1.2 Sarepta Therapeutics Business Overview
  4. 7.1.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sarepta Therapeutics Antisense Oligonucleotide Therapies Product Portfolio
  6. 7.1.5 Sarepta Therapeutics Recent Developments
  7. 7.2 Nippon Shinyaku
  8. 7.2.1 Nippon Shinyaku Company Information
  9. 7.2.2 Nippon Shinyaku Business Overview
  10. 7.2.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Nippon Shinyaku Antisense Oligonucleotide Therapies Product Portfolio
  12. 7.2.5 Nippon Shinyaku Recent Developments
  13. 7.3 Ionis Pharmaceuticals
  14. 7.3.1 Ionis Pharmaceuticals Company Information
  15. 7.3.2 Ionis Pharmaceuticals Business Overview
  16. 7.3.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product Portfolio
  18. 7.3.5 Ionis Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Antisense Oligonucleotide Therapies Revenue (2021-2032)
  2. 8.2 North America Antisense Oligonucleotide Therapies Revenue by Type (2021-2032)
  3. 8.2.1 North America Antisense Oligonucleotide Therapies Revenue by Type (2021-2026)
  4. 8.2.2 North America Antisense Oligonucleotide Therapies Revenue by Type (2027-2032)
  5. 8.3 North America Antisense Oligonucleotide Therapies Revenue Share by Type (2021-2032)
  6. 8.4 North America Antisense Oligonucleotide Therapies Revenue by Application (2021-2032)
  7. 8.4.1 North America Antisense Oligonucleotide Therapies Revenue by Application (2021-2026)
  8. 8.4.2 North America Antisense Oligonucleotide Therapies Revenue by Application (2027-2032)
  9. 8.5 North America Antisense Oligonucleotide Therapies Revenue Share by Application (2021-2032)
  10. 8.6 North America Antisense Oligonucleotide Therapies Revenue by Country
  11. 8.6.1 North America Antisense Oligonucleotide Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Antisense Oligonucleotide Therapies Revenue by Country (2021-2026)
  13. 8.6.3 North America Antisense Oligonucleotide Therapies Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Antisense Oligonucleotide Therapies Revenue (2021-2032)
  2. 9.2 Europe Antisense Oligonucleotide Therapies Revenue by Type (2021-2032)
  3. 9.2.1 Europe Antisense Oligonucleotide Therapies Revenue by Type (2021-2026)
  4. 9.2.2 Europe Antisense Oligonucleotide Therapies Revenue by Type (2027-2032)
  5. 9.3 Europe Antisense Oligonucleotide Therapies Revenue Share by Type (2021-2032)
  6. 9.4 Europe Antisense Oligonucleotide Therapies Revenue by Application (2021-2032)
  7. 9.4.1 Europe Antisense Oligonucleotide Therapies Revenue by Application (2021-2026)
  8. 9.4.2 Europe Antisense Oligonucleotide Therapies Revenue by Application (2027-2032)
  9. 9.5 Europe Antisense Oligonucleotide Therapies Revenue Share by Application (2021-2032)
  10. 9.6 Europe Antisense Oligonucleotide Therapies Revenue by Country
  11. 9.6.1 Europe Antisense Oligonucleotide Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Antisense Oligonucleotide Therapies Revenue by Country (2021-2026)
  13. 9.6.3 Europe Antisense Oligonucleotide Therapies Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Antisense Oligonucleotide Therapies Revenue (2021-2032)
  2. 10.2 China Antisense Oligonucleotide Therapies Revenue by Type (2021-2032)
  3. 10.2.1 China Antisense Oligonucleotide Therapies Revenue by Type (2021-2026)
  4. 10.2.2 China Antisense Oligonucleotide Therapies Revenue by Type (2027-2032)
  5. 10.3 China Antisense Oligonucleotide Therapies Revenue Share by Type (2021-2032)
  6. 10.4 China Antisense Oligonucleotide Therapies Revenue by Application (2021-2032)
  7. 10.4.1 China Antisense Oligonucleotide Therapies Revenue by Application (2021-2026)
  8. 10.4.2 China Antisense Oligonucleotide Therapies Revenue by Application (2027-2032)
  9. 10.5 China Antisense Oligonucleotide Therapies Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antisense Oligonucleotide Therapies Revenue (2021-2032)
  2. 11.2 Asia Antisense Oligonucleotide Therapies Revenue by Type (2021-2032)
  3. 11.2.1 Asia Antisense Oligonucleotide Therapies Revenue by Type (2021-2026)
  4. 11.2.2 Asia Antisense Oligonucleotide Therapies Revenue by Type (2027-2032)
  5. 11.3 Asia Antisense Oligonucleotide Therapies Revenue Share by Type (2021-2032)
  6. 11.4 Asia Antisense Oligonucleotide Therapies Revenue by Application (2021-2032)
  7. 11.4.1 Asia Antisense Oligonucleotide Therapies Revenue by Application (2021-2026)
  8. 11.4.2 Asia Antisense Oligonucleotide Therapies Revenue by Application (2027-2032)
  9. 11.5 Asia Antisense Oligonucleotide Therapies Revenue Share by Application (2021-2032)
  10. 11.6 Asia Antisense Oligonucleotide Therapies Revenue by Country
  11. 11.6.1 Asia Antisense Oligonucleotide Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Antisense Oligonucleotide Therapies Revenue by Country (2021-2026)
  13. 11.6.3 Asia Antisense Oligonucleotide Therapies Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antisense Oligonucleotide Therapies Revenue (2021-2032)
  2. 12.2 SAMEA Antisense Oligonucleotide Therapies Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Antisense Oligonucleotide Therapies Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Antisense Oligonucleotide Therapies Revenue by Type (2027-2032)
  5. 12.3 SAMEA Antisense Oligonucleotide Therapies Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Antisense Oligonucleotide Therapies Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Antisense Oligonucleotide Therapies Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Antisense Oligonucleotide Therapies Revenue by Application (2027-2032)
  9. 12.5 SAMEA Antisense Oligonucleotide Therapies Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Antisense Oligonucleotide Therapies Revenue by Country
  11. 12.6.1 SAMEA Antisense Oligonucleotide Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Antisense Oligonucleotide Therapies Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Antisense Oligonucleotide Therapies Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst